248 related articles for article (PubMed ID: 31303188)
21. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease.
Lin JJ; Yueh KC; Liu CS; Liu JT; Lin SZ
Acta Neurol Taiwan; 2007 Sep; 16(3):150-7. PubMed ID: 17966954
[TBL] [Abstract][Full Text] [Related]
22. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Miller JW; Selhub J; Nadeau MR; Thomas CA; Feldman RG; Wolf PA
Neurology; 2003 Apr; 60(7):1125-9. PubMed ID: 12682318
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.
Phokaewvarangkul O; Bhidayasiri R; Garcia-Ruiz P; Odin P; Riederer P; Müller T
J Neural Transm (Vienna); 2023 Nov; 130(11):1451-1462. PubMed ID: 37603058
[TBL] [Abstract][Full Text] [Related]
24. The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson's disease.
Müller T; Riederer P
J Neural Transm (Vienna); 2024 Jun; 131(6):631-638. PubMed ID: 37329350
[TBL] [Abstract][Full Text] [Related]
25. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
[TBL] [Abstract][Full Text] [Related]
26. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
[TBL] [Abstract][Full Text] [Related]
27. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
[TBL] [Abstract][Full Text] [Related]
28. C677T polymorphism of the methylenetetrahydrofolate reductase gene does not affect folic acid, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.
Erdogan MO; Yildiz SH; Solak M; Eser O; Cosar E; Eser B; Koken R; Buyukbas S
Genet Mol Res; 2010 Jun; 9(2):1197-203. PubMed ID: 20589617
[TBL] [Abstract][Full Text] [Related]
29. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?
Zoccolella S; dell'Aquila C; Specchio LM; Logroscino G; Lamberti P
Curr Med Chem; 2010; 17(3):213-21. PubMed ID: 20214564
[TBL] [Abstract][Full Text] [Related]
30. Role of homocysteine in the treatment of Parkinson's disease.
Müller T
Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
[TBL] [Abstract][Full Text] [Related]
31. Folate, vitamin B12 and vitamin B6 and one carbon metabolism.
Selhub J
J Nutr Health Aging; 2002; 6(1):39-42. PubMed ID: 11813080
[TBL] [Abstract][Full Text] [Related]
32. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
[TBL] [Abstract][Full Text] [Related]
33. One-Carbon Metabolism in Alzheimer's Disease and Parkinson's Disease Brain Tissue.
Kalecký K; Ashcraft P; Bottiglieri T
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276958
[TBL] [Abstract][Full Text] [Related]
34. B-vitamins, homocysteine metabolism and CVD.
Strain JJ; Dowey L; Ward M; Pentieva K; McNulty H
Proc Nutr Soc; 2004 Nov; 63(4):597-603. PubMed ID: 15831132
[TBL] [Abstract][Full Text] [Related]
35. Update on cobalamin, folate, and homocysteine.
Carmel R; Green R; Rosenblatt DS; Watkins D
Hematology Am Soc Hematol Educ Program; 2003; ():62-81. PubMed ID: 14633777
[TBL] [Abstract][Full Text] [Related]
36. Homocysteine and Stroke Risk: Modifying Effect of Methylenetetrahydrofolate Reductase C677T Polymorphism and Folic Acid Intervention.
Zhao M; Wang X; He M; Qin X; Tang G; Huo Y; Li J; Fu J; Huang X; Cheng X; Wang B; Hou FF; Sun N; Cai Y
Stroke; 2017 May; 48(5):1183-1190. PubMed ID: 28360116
[TBL] [Abstract][Full Text] [Related]
37. The complex relationship between folate/homocysteine metabolism and risk of Down syndrome.
Coppedè F
Mutat Res; 2009; 682(1):54-70. PubMed ID: 19524060
[TBL] [Abstract][Full Text] [Related]
38. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.
Wu YL; Ding XX; Sun YH; Yang HY; Sun L
J Neurol Sci; 2013 Dec; 335(1-2):14-21. PubMed ID: 24064257
[TBL] [Abstract][Full Text] [Related]
39. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
[TBL] [Abstract][Full Text] [Related]
40. C(1) metabolism and CVD outcomes in older adults.
McNulty H; Strain JJ; Pentieva K; Ward M
Proc Nutr Soc; 2012 May; 71(2):213-21. PubMed ID: 22152927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
